Greater Manchester has been chosen to host a ground-breaking study into the long-term effects of obesity drugs With up to 3,000 people being asked to take part
The announcement has been made as part of a collaboration agreed between Lilly and UK Government today, unveiled at the Government’s International Investment Summit.
The study will evaluate the real-world effectiveness of tirzepatide in weight loss, diabetes prevention, and prevention of obesity-related complications for adults with obesity.
The evidence generated will seek to increase the global evidence base on the long-term impacts of weight loss medicines and potentially inform the UK’s care pathway approach to the treatment of obesity.
Significantly, the five-year study will also aim to collect data on healthcare resource utilisation, health-related quality of life and changes in participants’ employment status and sick days from work.
Obesity is the second biggest preventable cause of cancer and a major contributor to ill-health that prevents people from participating fully in work. This collaboration will bring together treatments and technologies developed by the life sciences sector and the health system seeking to demonstrate improved long-term health outcomes for those living with obesity.
Mayor of Greater Manchester, Andy Burnham, said: “Greater Manchester is world-renowned as a hub for innovation in health and life sciences. The results of the trial announced today could have a far-reaching impact on how we treat obesity globally, and our city-region is ready to make a significant contribution through our outstanding health data assets, R&D expertise, and the strong partnerships between industry, universities and public sector organisations.
“The International Investment Summit will provide an opportunity to showcase our local strengths in health innovation to an audience of global business leaders and investors. This partnership could be the first of many and give Greater Manchester residents access to other innovative treatments.”
